Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation

• US 10,208,050 B2
• Filed: 08/04/2017
• Issued: 02/19/2019
• Est. Priority Date: 07/12/2007
• Status: Active Grant

• Current Assignee: ChemoCentryx, Inc. (Amgen Inc.)
• Original Assignee: ChemoCentryx, Inc. (Amgen Inc.)
• Inventors: Krasinski, Antoni, Punna, Sreenivas, Ungashe, Solomon, Wang, Qiang, Zeng, Yibin
• Primary Examiner(s): Murray, Jeffrey H
• Application Number:
  US15/669,410
• Publication Number:
  US 20170334920A1
• Time in Patent Office: 564 Days
• Field of Search: 5142621, 51426322, 5142651, 5142611, 544262, 544277, 544280, 544254
• CPC Class Codes: A61P 31/06 for tuberculosis
• CPC Class Codes: C07D 213/79 Acids; Esters
• CPC Class Codes: C07D 213/81 Amides; Imides
• CPC Class Codes: C07D 213/84 Nitriles
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 471/12 in which the condensed system contains three hetero rings
• CPC Class Codes: C07D 473/00 Heterocyclic compounds containing purine ring systems
• CPC Class Codes: C07D 487/04 Ortho-condensed systems

Abstract

Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases and as controls in assays for the identification of CCR2 antagonists.

Claims

1. A method of treating a CCR2-mediated condition or disease, comprising administering to a subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

2. The method of claim 1, wherein R³, R⁴, and R⁶ are each hydrogen.

3. The method of claim 1, wherein R¹ is halogen and R² is C_1-8 haloalkyl.

4. The method of claim 1, wherein R⁵ is C_1-8 alkyl.

5. The method of claim 1, wherein R¹ is Cl;

R² is CF₃; and

R⁵ is methyl.

6. The method of claim 1, wherein the compound or pharmaceutically acceptable salt thereof is of formula (II)

7. The method of claim 6, wherein R¹ is halogen and R² is C_1-8 haloalkyl.

8. The method of claim 6, wherein R¹ is Cl and R² is CF₃.

9. The method of claim 6, wherein R⁵ is methyl.

10. The method of claim 1, wherein said CCR2-mediated condition or disease is psoriasis.

11. The method of claim 1, wherein said CCR2-mediated condition or disease graft-versus-host disease.

12. The method of claim 1, wherein said CCR2-mediated condition or disease is transplantation rejection.

13. The method of claim 1, further comprising administering a therapeutically effective amount of a second therapeutic agent.

14. A method of treating a CCR2-mediated condition or disease, comprising administering to a subject a therapeutically effective amount of a compound of formula

15. The method of claim 14, wherein said CCR2-mediated condition or disease is psoriasis.

16. The method of claim 14, wherein said CCR2-mediated condition or disease graft-versus-host disease.

17. The method of claim 14, wherein said CCR2-mediated condition or disease is transplantation rejection.

18. The method of claim 14, further comprising administering a therapeutically effective amount of a second therapeutic agent.